Polen Focus Growth Exits Abbott Laboratories (ABT) in Q1 2026
Polen Focus Growth Strategy exited its position in Abbott Laboratories (ABT) in Q1 2026 due to concerns over the company's acquisition of Exact Sciences, which was deemed dilutive. The strategy experienced a 17.16% decline in the quarter, outperforming the Russell 1000 Growth and S&P 500 indices. Abbott Laboratories closed at $93.86 per share on April 28, 2026, with a one-month return of -8.32%.
Topics: Abbott Laboratories investment strategy Polen Capital portfolio changes